New biomarkers for primary mitral regurgitation

Table 2 Routine clinical assays

Variables	HC	MR severity			p values
Variables	HC	Mild	Moderate	Severe
Cohort 1^a	(n = 16)	(n = 23)	(n = 21)	(n = 20)
Cohort 2^b	(n = 14)	(n = 10)	(n = 16)	(n = 19)	A	B
Inflammatory markers
CRP^a (mg/mL)	2.89 ± 2.69	1.50 ± 2.12	2.35 ± 3.13	1.51 ± 1.20	0.18	0.46
MPO^a (ηg/mL)	32.08 ± 17.71	20.83 ± 6.27	35.06 ± 30.72	41.90 ± 36.12	0.10	0.16
Heart failure markers
BNP^a (pg/mL)	–	47.76 ± 35.82	73.35 ± 105.4	54.04 ± 30.83	–	0.72
Lipids
Total cholesterol^b (g/L)	2.12 ± 0.38	2.25 ± 0.20	2.04 ± 0.47	2.07 ± 0.35	0.57	0.37
HDL^b (g/L)	0.64 ± 0.17	0.71 ± 0.06	0.61 ± 0.12	0.52 ± 0.15	0.01	0.008
LDL^b (g/L)	1.48 ± 1.25	1.31 ± 0.17	1.19 ± 0.43	1.24 ± 0.35	0.40	0.37
Triglycerides^b (g/L)	1.67 ± 1.21	1.12 ± 0.35	1.20 ± 0.48	1.56 ± 0.63	0.31	0.11
ApoA1^b (g/L)	1.74 ± 0.25	1.77 ± 0.17	1.63 ± 0.21	1.45 ± 0.22	0.002	0.002
ApoB^b (g/L)	0.99 ± 0.28	1.00 ± 0.16	0.94 ± 0.31	1.02 ± 0.27	0.75	0.60
OLDL^b (ηg/mL)	281.6 ± 210.2	497.2 ± 663.1	631.3 ± 830	763.2 ± 643.1	0.47	0.52
ALDL^b (UI/L)	390.6 ± 139.9	620.3 ± 401	707.3 ± 371	608.5 ± 402.3	0.31	0.18

Data are expressed as the mean ± SD
A: Comparisons between the 4 groups; B: Comparisons between the 3 MR groups
MR mitral regurgitation, HC healthy controls, CRP C-reactive protein, MPO myeloperoxidase, BNP B-type natriuretic peptide, HDL high-density lipoprotein, LDL light-density lipoprotein, Apo apo-lipoprotein, OLDL oxidized-LDL, ALDL antibody against OLDL
^aCohort 1: whole cohort
^bCohort 2: cohort without cholesterol-lowering medication

ISSN: 1559-0275